Top Markets
#1 GEKKO GEKKO +52.86%
#2 Helium Helium +48.09%
#3 Pons Pons +29.16%
#4 龙虾 (Lobster) 龙虾 (Lobster) +18.73%
#5 ADO Protocol ADO Protocol +18.06%
#6 Main Street Yield Main Street Yield +17.48%
#7 Collect on Fanable Collect on Fanable +16.65%
#8 OpenGradient OpenGradient +12.52%
#9 o1.exchange o1.exchange +12.13%
#10 Nillion Nillion +10.62%
Coin of the day
GEKKO GEKKO
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Inventiva S.A. Inventiva S.A.

Inventiva S.A.

IVA
Classement en actions #8990
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Prix de l'action
$4.74
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$1.12B
Changement (1 jour)
-5.77%
Changement (1 an)
-16.96%
Pays
FR
Échange Inventiva S.A. (IVA)

Catégorie

Healthcare
Ratio P/B pour Inventiva S.A. (IVA)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Inventiva S.A., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Inventiva S.A. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH